- Home
- / Daewon Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Daewon Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩14.5 K
2024-10-29
Market Capitalization
₩305.2 B
2024-10-29
Revenue
₩527 B
FY, 2023
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 286.7B | 317.8B | 308.5B | 354.2B | 478.9B | 527.0B |
| Cost of goods sold | 105.5B | 101.6B | 100.1B | 130.7B | 184.7B | 255.2B |
| Gross profit | 182.5B | 218.1B | 211.6B | 225.7B | 295.5B | 273.2B |
| Gross profit margin, % | 63.7% | 68.6% | 68.6% | 63.7% | 51.8% | |
| Operating expense total | 140.0B | 169.3B | 168.7B | 186.3B | 231.8B | 222.0B |
| Depreciation and amortization | 10.4B | 12.0B | 16.4B | 18.9B | 21.5B | 22.2B |
| EBITDA | 42.7B | 48.9B | 43.5B | 39.9B | 64.5B | 51.7B |
| EBITDA margin, % | 14.9% | 15.4% | 14.1% | 11.3% | 9.8% | |
| EBIT | 31.4B | 35.5B | 24.7B | 18.0B | 40.8B | 28.6B |
| EBIT margin, % | 11.0% | 11.2% | 8.0% | 5.1% | 5.4% | |
| Interest income | 590.9M | 237.8M | 160.5M | 270.5M | 1.1B | 1.3B |
| Interest expense | 664.5M | 268.6M | 1.2B | 2.1B | 3.7B | 4.6B |
| Pre tax profit | 31.2B | 35.4B | 23.6B | 17.1B | 38.7B | 25.8B |
| Income tax expense | 7.9B | 8.5B | 6.4B | 10.5B | 8.1B | 2.4B |
| Net Income | 23.3B | 26.9B | 17.2B | 6.6B | 30.7B | 23.5B |